Alea A. Mills
Ph.D., University of California, Irvine, 1997
Cells employ stringent controls to ensure that genes are turned on and off at the correct time and place. Accurate gene expression relies on several levels of regulation, including how DNA and its associated molecules are packed together. I study the diseases arising from defects in these control systems, such as aging and cancer.
Alea Mills is studying genetic pathways important in cancer, aging, and autism, identifying the genetic players and determining how aberrations in their functions culminate in human disease. Through innovative use of a technique called “chromosome engineering,” the Mills group discovered that one of the most common genetic alterations in autism—deletion of a 27-gene cluster on chromosome 16—causes autism-like features in mice. These autism-like movement impairments can be identified just days after birth, suggesting that these features could be used to diagnose autism. Mills has also used chromosome engineering to identify a tumor suppressor gene that had eluded investigators for three decades. The gene, called Chd5, was shown by Mills to regulate an extensive cancer-preventing network. This year, the Mills lab uncovered how Chd5 acts as a tumor suppressor: It binds to a protein found within chromatin to turn specific genes on or off, halting cancer progression. The epigenetic role of Chd5 in development, cancer, and stem-cell maintenance is currently being investigated. The Mills lab is also studying p63 proteins, which regulate development, tumorigenesis, cellular senescence, and aging in vivo. They succeeded in halting the growth of malignant tumors by turning on production of one of the proteins encoded by the p63 gene, called TAp63. TAp63 also exerts other protective effects. This year, the Mills lab generated a mouse model which allowed them to find that TAp63 is required to prevent a genetic disorder, known as EEC (ectrodactyly-ectodermal dysplasia cleft lip/palate syndrome), which is characterized by a cleft palate and major deformities of the skin and limbs in infants. In addition, they recently discovered that a different version of p63, called ΔNp63, reprograms stem cells of the skin to cause carcinoma development—the most prevalent form of human cancer. Modulation of these proteins may offer new ways to treat human malignancies in the future.
Keyes, W.M., Pecorasro, M., Aranda, V., Vernersson-Lindahl, E., Li, W., Vogel, H., Guo, X., Garcia, E.M., Michurina, T.V., Enikolopov, G., Muthuswamy, S.K., and Mills, A.A. 2011. DeltaNp63alpha is an oncogene that targets chromatin remodeler Lsh to drive skin stem cell proliferation and tumorigenesis. Cell Stem Cell 2: 164–176.
Mills, A.A. 2010. Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. Nat. Rev. Cancer 10: 669–682.
Guo, X., Keyes, W.M., Papazoglu, C., Zuber, J., Li W., Lowe, S.W., Vogel, H., and Mills, A.A. 2009. TAp63 induces senescence and suppresses tumorigenesis in vivo. Nature Cell Biol. 11: 1451–1457.
Bagchi, A., and Mills, A.A. 2008. The quest for the 1p36 tumor suppressor. Cancer Research 68: 2551–2556.
Bagchi, A., Papazoglu, C., Wu, Y., Capurso, D., Brodt, M., Francis, D., Bredel, M., Vogel, H., and Mills, A.A. 2007. CHD5 is a tumor suppressor at human 1p36. Cell 128: 459–475.
Male infertility: it’s all about the package
May 13, 2014
CSHL geneticists solve mystery of EEC Syndrome's variable severity in children
June 14, 2013
Cancer scientists determine mechanism of one of the most powerful tumor-suppressor proteins, Chd5
January 10, 2013
CSHL team finds evidence for the genetic basis of autism
Study finds a stem cell origin of skin cancer and the genetic lesions that promote its malignancy
Alea Mills named "Woman of the Year in Health/Medicine"
December 27, 2012
My group is focused on defining how chromatin dynamics controls differentiation of neural stem cells, dendritic architecture, and behavior. We use a multi-faceted functional approach to elucidate genetic/epigenetic processes controlling brain pathologies, and generate novel models for neurological syndromes that could pave the way for designing more effective clinical interventions.